Filter Releases
 
News Releases
Date Title and Summary View
Jun 4, 2012
Montreal, Canada. June 4, 2012 – MethylGene Inc. (TSX:MYG) today announced that clinical data for its Met/VEGFR multi- kinase inhibitor MGCD265 was presented in a poster session at the 2012 ASCO Annual Meeting held in Chicago, Illinois. The poster, entitled “MGCD265, a multitargeted oral tyrosine kinase recept...
May 29, 2012
Montreal, Canada. May 29, 2012 – MethylGene Inc. (TSX:MYG) today announced that clinical data for its Met/VEGF-R kinase inhibitor, MGCD265, will be presented at the 2012 ASCO Annual Meeting to be held in Chicago, Illinois from June 1 to 5, 2012. This poster presentation will highlight the safety profile of MGC...
May 23, 2012
Montreal, Canada. May 23, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Joseph Walewicz, Vice President, Business and Corporate Development, will present an overview of the Company at the BioFinance 2012 Conference which will be held at the St. Andrew’s Club & Conference Centre in Toronto. Mr. Walewicz will be pres...
May 14, 2012
Montreal, Canada.  May 14, 2012 – MethylGene Inc. (TSX: MYG) today reported financial results for the first quarter ended March 31, 2012 and provided an update on clinical programs.  Highlights  Rachel W. Humphrey, MD was appointed as Executive Vice President and Chief...
Apr 2, 2012
Montreal, Canada. April 2, 2012 – MethylGene Inc. (TSX:MYG) today disclosed preclinical data during a presentation for its proprietary multi-targeted kinase inhibitor, MGCD265, at the 2012 AACR Annual Meeting held in Chicago, Illinois. Results were presented showing the potent inhibition of tumor growth ...
Mar 28, 2012
Montreal, Quebec. March 28, 2012 – MethylGene Inc. (TSX:MYG) today announced that preclinical data for its multi-targeted kinase inhibitor, MGCD265, will be reported in a poster session at the 2012 American Association for Cancer Research (AACR) Annual Meeting to be held in Chicago, Illinois from March 31 to A...
Mar 19, 2012
Montreal, Quebec. March 19, 2012 – MethylGene Inc. (TSX: MYG) today announced the appointment of Peggy Mulligan, FCA to the Company’s Board of Directors. “Peggy is a financial and audit expert, and a well respected business leader. We look forward to her guidance as we plan for the future”, said Charles Grubsztajn, Pre...
Mar 15, 2012
Montreal, Quebec.  March 15, 2012 – MethylGene Inc. (TSX: MYG) today reported financial results for the fourth quarter and full year ended December 31, 2011. Highlights During the fourth quarter we commenced our first randomized, controlled Phase 2 study with MGCD290, and our two Phase 1 dose escalation ...
Feb 7, 2012
Montreal, Canada.  February 7, 2012 – MethylGene Inc. (TSX: MYG) announced today that Mr. Charles Grubsztajn, President and Chief Executive Officer, will present a corporate overview of the Company on Monday, February 13 at 4:30 p.m. EST, at the 14th Annual BIO CEO & Investor Conference. The event is being held at the Wa...
Feb 2, 2012
Montreal, Quebec. February 2, 2012 – MethylGene Inc. (TSX: MYG) is pleased to announce the appointment of Dr. Henry J. Fuchs to the Company’s Board of Directors. “Dr. Fuchs is a highly regarded leader in the biotechnology industry and brings a wealth of drug development and management experience at public life science ...
Jan 4, 2012
Montreal, Quebec. January 4, 2012 – MethylGene Inc. (TSX: MYG) today announced the appointment of Rachel Humphrey, MD, to the post of Executive Vice President and Chief Medical Officer. Dr. Humphrey is board certified in Medical Oncology and has led the development of multiple oncology agents, two of which are currently commerciali...
Page: First Previous
...
 
= add release to Briefcase